Zheng Quan Zhi Xing·2025-08-22 14:17Core Viewpoint - The company is implementing an A-share option incentive plan aimed at enhancing corporate governance, attracting and retaining talent, and aligning the interests of shareholders, the company, and its core team for long-term development [3][4]. Group 1: Company Overview - Fosun Pharma was listed on the Shanghai Stock Exchange on August 7, 1998, and on the Hong Kong Stock Exchange on October 30, 2012 [2]. - As of August 22, 2025, the total share capital of the company is 2,670,429,325 shares, comprising 2,118,488,825 A-shares and 551,940,500 H-shares [2]. - The company operates in the fields of biochemical products, reagents, and related consulting services, among others [2]. Group 2: Incentive Plan Details - The total number of A-share options to be granted under the plan is capped at 5,726,100, which corresponds to 0.2144% of the company's total shares [4][5]. - The initial grant will consist of 4,580,900 options (80% of the total), while 1,145,200 options (20%) will be reserved for future grants [5][6]. - The A-share options will be sourced from shares repurchased from the secondary market [4][6]. Group 3: Objectives and Benefits - The plan aims to improve corporate governance and establish a long-term incentive mechanism to motivate executives and employees [3][4]. - It seeks to align the interests of shareholders, the company, and its core team, fostering a collective focus on the company's long-term growth [3][4]. Group 4: Grant and Exercise Conditions - The exercise price for the initial grant of A-share options is set at 27.93 yuan per share, based on the average trading price prior to the announcement [10]. - The plan includes a waiting period before options can be exercised, with specific timelines for different tranches of options [11][12]. - The plan stipulates that the options can only be exercised if certain financial performance criteria are met, including net profit and revenue from innovative drugs [14][15]. Group 5: Financial Impact and Accounting - The total estimated expense for the initial grant of 4,580,900 A-share options is projected to be 12.14 million yuan, which will be amortized over the plan's duration [30][31]. - The plan's implementation is expected to have a positive impact on the company's performance, potentially outweighing the associated costs [31].